Objectives-To examine the effects of drug treatment on laboratory exercise tests in relation to measures of daily activity in patients with chronic heart failure. Setting University teaching hospital. Subjects-18 patients with mild to moderate chronic heart failure (New York Heart Association functional class II-III) and 10 age matched healthy controls. Methods-Assessments were made before and after 12 weeks of vasodilator drug treatment. Exercise capacity was measured during two different types of treadmill exercise, one using a ramp protocol and the other a fixed work load. Corridor walk tests at three self selected speeds were also undertaken and measures of customary activity assessed from pedometer scores. Results-Exercise times were significantly increased from baseline (P < 0.01) with both treadmill protocols after 12 weeks of drug treatment, with a positive correlation between the duration of treadmill exercise for both protocols (r = 0-69, P < 0.01). Corridor walk tests of 100 m at a self selected slow speed also improved (P < 0.02) but these did not correlate with the changes in treadmill exercise time. The pedometer scores of the patients with heart failure were greatly reduced compared with those of the controls (258 (45) x 102 v 619 (67) x 102 stepslweek, P < 0.001) and after 12 weeks of treatment were unchanged (261 (42) x 102 steps/week). Conclusions-These data confirm the need to use different exercise protocols when assessing the benefits of drug treatment in patients with chronic heart failure. Treatments that seem effective with conventional laboratory based exercise tests may not improve daily activities. This may reflect a failure of apparently successful treatment and should be considered when intepreting clinical trials. (Br Heartj_ 1995;70:373-376) 
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(Br Heartj_ 1995;70:373-376) Keywords : chronic heart failure; exercise protocols; exercise capacity; effects of drug treatment An improvement in symptomatic wellbeing is an important aim in the treatment of patients with chronic heart failure but the best way of assessing it is not clear. Formerly, favourable changes in central haemodynamic variables were believed to indicate a beneficial effect of treatment but it is now recognised that they may not be matched by changes in the patient's exercise capability.1 2 As exercise capability is thought to be closely related to wellbeing, laboratory based, symptom limited exercise tests performed on a treadmill or bicycle are the usual way of assessing the effects of drugs. These tests have the advantage of close control but clearly are not representative of the type of exercise that patients perform during normal daily life.3 Different exercise protocols also seem to give different measures of incapacity and which is the most appropriate is not known. 4 For these reasons other tests, such as corridor walk tests, in which patients decide their own work load are being used more frequently. These are of two types: those that are also symptom limited, patients walking as far as possible in an allotted time,5 and those that measure perception of speed in which patients are asked to walk a fixed distance at self selected speeds.6 Although these tests are more likely to be representative of daily incapacity, they remain laboratory based and as such may still not accurately reflect actual exercise capability outside of this environment.
Assessment of patients outside the laboratory often involves the use of quality of life questionnaires, many of which specifically enquire about levels of daily activity. Additional information may also be obtained using body borne pedometers, which have shown a greatly reduced level of daily activity in patients with heart failure compared with that in normal controls.47 Ideally, an effective drug should be able to increase this aspect of a patient's exercise capability and produce a real improvement in wellbeing. We 
Patients and methods

PATIENTS
Eighteen patients with moderate to severe heart failure were studied. They were participating in two trials that compared the effects of captopril and the oral dopamine agonist ibopamine, and isosorbide mononitrate and the angiotensin converting enzyme inhibitor, trandolapril. The patients' ages ranged from 56 to 75 years and 14 were men. The cause of heart failure was ischaemic heart disease in 10 patients, mitral or aortic regurgitation with impaired left ventricular function in four, and dilated cardiomyopathy in the remaining four. All patients were limited on exertion by symptoms of heart failure despite at least 80 mg of frusemide daily (mean (range) dose was 90 (80-160) mg). The studies were approved by the local ethics committee and all patients gave informed written consent.
Customary activity of 10 fit healthy controls of the same age as the patients was measured over a one week period.
METHODS
All patients were evaluated in an identical way. In addition to their normal medication they were given, single blind, placebo treatment. This was continued until their treadmill exercise time measured at weekly intervals using a modified Bruce protocol had reached a plateau and did not increase by more than 5% on two consecutive visits. Patients were then randomised to one of the active treatments and repeat measurements of exercise capacity were made at the end of 12 weeks of treatment.
TREADMILL EXERCISE TESTS
At each visit the patients were asked to exercise to a symptom limited maximum using two different treadmill protocols. The first was a modified Bruce protocol; the speed and slope of the treadmill increasing after three min at each of the following stages: Stage Speed (km/h) Slope' I II III IV V 2-7 2-7 2-7 2-7 4-0 0 1-3 2-6 4.3 5.4 VI 5-4 6-3
After at least 45 min of rest the patients were asked to complete a second symptom limited test. The speed and slope of the treadmill were fixed at the equivalent to stage IV of the modified Bruce protocol and patients continued at this work load until stopped by symptoms of heart failure. Absolute work completed was calculated in kilojoules from standard formulae during both exercise tests.
were accepted only if the readings from both pedometers were within 20% of each other and a mean score was then calculated.
STATISTICAL ANALYSIS
Data are expressed as means (SEM). Analysis of the differences between variables before and after treatment was made with the Wilcoxon signed rank test. Analysis of the relations between the changes of the different variables was performed with Spearman's rank correlation coefficient.
Results
TREADMILL EXERCISE TESTS
The mean (SEM) symptom limited exercise time increased with both treadmill protocols (fig 1) . Using the modified Bruce protocol exercise duration increased from 414 (70) s to 651 (68) s (P < 0 01). The baseline exercise duration was shorter with the fixed protocol (P < 0 01) but this also increased with treatment from 267 (50) s to 541 (106) s (P < 0 01). Figure 2 shows the correlation of the changes between the two treadmill protocols after treatment (r = 0-69, P < 0 05).
The mean (SEM) work performed also increased from 5-81 (1-75) kJ to 13-98 (2.93) kJ (P < 0 01) using the modified Bruce protocol, and from 11-88 (2 43) kJ to 34 09 (10 9) kJ (P < 0 01) with the fixed protocol. The baseline exercise capability assessed by total work was greater with the fixed protocol than the Bruce protocol (P < 0.01). There was a significant correlation between the protocols in respect of work completed (r = 0 5, P < 0 05).
CORRIDOR WALK TESTS
The mean (SEM) time taken for patients with heart failure to walk 100 m at a self paced slow speed decreased from 109 (6) s to 102 (6) s (P < 0 02) after treatment. Treatment had no significant effect at the normal (from 87 (4) s to 85 (5) s) and fast speeds (from 74 (0 2) s to 73 (4) s). There were no significant correlations between the corridor walk tests and any aspect of treadmill exercise tolerance ( All patients received active treatment and after 12 weeks' treatment exercise tolerance was improved when assessed on the treadmill. It seems likely that such a significant increase reflects a true response to active treatment rather than a placebo effect, although a placebo control group was not included in the study. There was also a correlation between the changes with both protocols but the magnitude of the changes differed according to the protocol used. This clearly indicates that the measurement of incapacity and the response to treatment are dependent on the exercise protocol used. The treatments also improved the corridor walk test at the self selected slow pace with no significant effect at normal or fast speeds. This is similar to other studies that have reported improvement only at the slow speed.46 There was no correlation between the changes in corridor walk tests and the other tests.
Despite 
